BioSpace News Archive

Drug Development

FDA Slaps Breakthrough Tag on Eisai, Merck’s Combo Renal Cell Carcinoma Drug

The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.

January 9, 2018
·
2 min read
·
Alex Keown
Policy

Parents Accuse Vtesse, Sucampo of Stealing Data From Their Sick Children

The suit, filed in Nevada Friday, comes after Vtesse was purchased by Sucampo for $200 million in April.

January 9, 2018
·
1 min read
Biotech Beach

5 Top Biotech Stocks That Look Vulnerable in 2018

Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.

January 9, 2018
·
3 min read
·
Mark Terry
Lepu Medical Pays $23.3M for 13% Stake in Australia’s Viralytics

Viralytics will use the funds for an Australian Phase III trial of CAVATAK, its oncolytic immunotherapy based on a common cold virus.

January 9, 2018
·
1 min read
Business

Adaptimmune’s CMO Moves Forward With SPEAR T Cell Therapies

Adaptimmune is making strides on becoming a fully integrated cell therapy company behind its T Cell Receptor technology

January 9, 2018
·
3 min read
·
Alex Keown
Biotech Beach

Crown Bioscience Launches CrownSyn, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies

CrownSyn is now available as an add-on feature to all two-drug combinatorial studies conducted by Crown Bioscience.

January 9, 2018
·
2 min read
Shire to Break Up Business Into Two Companies

Shire is splitting into two separate internal business units, Rare Disease Division and Neuroscience Division.

January 9, 2018
·
2 min read
·
Mark Terry
Deals

Why Pfizer Could and Should Make Another Move on Allergan

Since the acquisition fell apart, Allergan has fallen on some hard times.

January 9, 2018
·
2 min read
·
Alex Keown
Biotech Bay

3 Must-Buy Biotech Stocks for January

These prominent drug developers look to be enticing buys this month.

January 9, 2018
·
1 min read
Business

Medtronic CEO Talks Value-Based Care, Addresses Criticism of M&A Strategy at JPM

In his opening presentation at JPM, he highlighted one major product to show how the Irish medtech company is pursuing value-based care.

January 9, 2018
·
1 min read